Basket
Specific theme-based reports aggregated and discounted to offer the investor comprehensive insight about a specific theme at a value price. Various reports are consolidated to offer valuable information about a particular industry event, a disease or a company.
|
|
Sample Report:
VRTX's HCV drug Telaprevir received FDA approval on May 23, 2011. New BioMedicine had issued a report on this event on May 3, 2011. To read more about the drug, the disease, the market, the competition, etc. access it at the link below.
|
| |
Basket Reports: |
 |
Specific theme-based reports at a value price
|
View Package |
|
|
